EGFR and non-small cell lung carcinoma: Osimertinib, one of the most successful EGFR tyrosine kinase inhibitors (EGFR‐TKIs), has demonstrated significant improvements in median progression‐free survival (PFS) and overall survival (OS) for NSCLC patients with EGFR mutations.10, 11